AAD 2024
Efficacy of Risankizumab Versus Apremilast Among Patients with Scalp or Nail Psoriasis from the Phase 4 IMMpulse Study
This session was presented on March 8 2024 at the
This session was presented on March 8 2024 at the
This session was presented on March 8 2024 at the
This session was presented on March 8 2024 at the
This session was presented on March 8 2024 at the
This session was presented on March 8 2024 at the
This session was presented on March 8 2024 at the